Roeser H P, Rohan A P
Department of Medicine, University of Queensland, Royal Brisbane Hospital, Herston.
Med J Aust. 1990;153(11-12):720-6. doi: 10.5694/j.1326-5377.1990.tb126333.x.
Post-marketing surveillance of drugs in Australia operates predominantly through the spontaneous reporting of suspected adverse drug reactions (ADRs). Approximately 50% of reports are submitted by hospitals and the rest by individual doctors, pharmacists and dentists. Some 4500 reports ("blue cards") are now reviewed annually by the Adverse Drug Reactions Advisory Committee (ADRAC) and its Secretariat. The register of ADRs has now accumulated more than 65,000 reports. Collations and analyses of data derived from the review process are published to increase awareness by health professionals of drug associated morbidity. Continued educational efforts by professional bodies and regulatory agencies will play a key role in rationalising drug use and reducing drug induced disease.
澳大利亚药品上市后监测主要通过自发报告疑似药物不良反应(ADR)来开展。约50%的报告由医院提交,其余由个体医生、药剂师和牙医提交。不良药物反应咨询委员会(ADRAC)及其秘书处每年会对约4500份报告(“蓝卡”)进行审查。药品不良反应登记册现已累积了超过65000份报告。对审查过程中获取的数据进行整理和分析并予以公布,以提高卫生专业人员对药物相关发病率的认识。专业团体和监管机构持续开展的教育工作将在合理用药和减少药物所致疾病方面发挥关键作用。